The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Centrosome amplification (CA) contributes to carcinogenesis by generating aneuploidy. Elevated frequencies of CA in most benign breast lesions and primary tumors suggest a causative role for CA in breast cancers. Clearly, identifying which and how altered signal transduction pathways contribute to CA is crucial to breast cancer control. Although a causative and cooperative role for c-Myc and Ras in mammary tumorigenesis is well documented, their ability to generate CA during mammary tumor initiation remains unexplored. To answer that question, K-RasG12D and c-Myc were induced in mouse mammary glands. Although CA was observed in mammary tumors initiated by c-Myc or K-RasG12D, it was detected only in premalignant mammary lesions expressing K-RasG12D. CA, both in vivo and in vitro, was associated with increased expression of the centrosome-regulatory proteins, cyclin D1 and Nek2. Abolishing the expression of cyclin D1, Cdk4 or Nek2 in MCF10A human mammary epithelial cells expressing H-RasG12V abrogated Ras-induced CA, whereas silencing cyclin E1 or B2 had no effect. Thus, we conclude that CA precedes mammary tumorigenesis, and interfering with centrosome-regulatory targets suppresses CA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 2×
“As ablation of cyclin D1 or Cdk4 abrogates mammary tumorigenesis in MMTV-Ras or MMTV-Neu (Her2) mice (Yu et al., 2001; Reddy et al., 2005), Cdk4/Cdk6-specific inhibitors reduce ectopic proliferation in human Her2+ breast cancer cells (Finn et al., 2009), and inhibitors of Nek2 decrease the…”
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878 · cited 4×
“In fact, of the five independent genetic alterations required to transform primary human mammary epithelial cells (Elenbaas et al., 2001), three (namely H-Ras, inactive Rb and p53) trigger CA and CIN (Fukasawa et al.”
InfluentialDose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490 · cited 10×
“Indeed, an active p53 pathway is a major obstacle to H-Ras-initiated mammary tumors (Hundley et al., 1997b; Sarkisian et al., 2007), and c-Myc triggers activating K-Ras mutations to induce nonregressing mammary tumors (D’Cruz et al.”
InfluentialSelf-citationCentrosome duplication in mammalian somatic cells requires E2F and Cdk2–Cyclin A
Meraldi, P., Lukas, J., Fry, A. M., Bartek, J., & Nigg, E. A. (1999) · Nature Cell Biology · doi:10.1038/10054 · Cited by 475 · cited 7×
“[PubMed: 10608877] Saavedra HI, Maiti B, Timmers C, Altura R, Tokuyama Y, Fukasawa K, et al. Inactivation of E2F3 results in centrosome amplification.”
InfluentialCarroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y.-Q., Tarapore, P., & Fukasawa, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202515 · Cited by 279 · cited 1×
“CA is frequently observed in human cancers—including prostate, colon, breast and cervical cancer—which suggests an involvement in tumorigenesis (Pihan et al., 1998; Carroll et al., 1999; Ghadimi et al., 2000; Lingle et al., 2002).”
RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts
Iovino, F., Lentini, L., Amato, A., & Di Leonardo, A. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-38 · Cited by 94 · cited 8×
“However, the source, timing and relevance of oncogene-dependent CIN to mammary tumorigenesis are unknown.”
InfluentialBERMAN, H., ZHANG, J., CRAWFORD, Y. G., GAUTHIER, M. L., FORDYCE, C. A., McDERMOTT, K. M., SIGAROUDINIA, M., KOZAKIEWICZ, K., & TLSTY, T. D. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.051 · Cited by 51
Cited by
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
A Clinical Overview of Centrosome Amplification in Human Cancers
Chan, J. Y. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.1122 · Cited by 379
Sun, C., Li, S., Zhang, F., Xi, Y., Wang, L., Bi, Y., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10108 · Cited by 312
The double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“[9] Zeng X, Shaikh FY, Harrison MK, et al.”
BackgroundThe Role of Aneuploidy in Cancer Evolution
Sansregret, L., & Swanton, C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028373 · Cited by 266
Metadata
- Authors
- Zeng, X., Shaikh, F. Y., Harrison, M. K., Adon, A. M., Trimboli, A. J., Carroll, K. A., Sharma, N., Timmers, C., Chodosh, L. A., Leone, G., & Saavedra, H. I.
- Venue
- Oncogene
- Published
- 2010-06-28
- Volume
- 29
- Issue
- 36
- Pages
- 5103-5112
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2021637770
- Cited by
- 78
- References
- 8
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.